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ABSTRACT
We have developed a humanized bi-speciﬁc T-cell engager (BiTE) targeting receptor tyrosine kinase-like
orphan receptor 1 (ROR1), a cell surface antigen present on a range of malignancies and cancer-initiating
cells. Focusing initially on pancreatic cancer, we demonstrated that our ROR1 BiTE results in T cell
mediated and antigen-speciﬁc cytotoxicity against ROR1-expressing pancreatic cancer cell lines in vitro at
exceedingly low concentrations (0.1 ng/mL) and low effector to target ratios. Our BiTE prevented
engraftment of pancreatic tumor xenografts in murine models and reduced the size of established
subcutaneous tumors by at least 3-fold. To validate its wider therapeutic potential, we next demonstrated
signiﬁcant cytotoxicity against ovarian cancer in an in vitro and in vivo setting and T-cell-mediated killing
of a range of histologically distinct solid tumor cell lines. Overall, our ROR1 BiTE represents a promising
immunotherapy approach, because of its ability to target a broad range of malignancies, many with
signiﬁcant unmet therapeutic needs.
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Introduction
Currently, over 8 million people die of cancer annually world-
wide1 and although cancer survival has doubled over the last
40 y, for some tumors such as pancreatic cancer the outlooks
remain dismal. Attention has therefore turned to immunother-
apy, which has achieved notable success in the treatment of
malignancies over the last decade. Monoclonal antibodies tar-
geting antigens expressed on tumors have improved survival in
patients with B cell lymphoid malignancies and breast cancer.2,3
Antibodies that activate endogenous T cells by blocking
immune checkpoints are beginning to generate durable clinical
responses in patients with melanoma, lung, renal, and bladder
cancers but appear to be less effective in certain tumors such as
pancreatic carcinoma.4-6 Adoptive T cell immunotherapy with
genetically modiﬁed T cells that express chimeric antigen
receptors (CARs) show great promise in the treatment of
hematological malignancies, especially in patients with refrac-
tory B-cell acute lymphoblastic leukemia (B-ALL).7,8 These
artiﬁcial receptors, consisting of a tumor-targeting single-chain
variable fragment linked to one or more intracellular T cell
receptor (TCR) signaling domains, enable targeting of tumor
antigens in an major histocompatibility complex (MHC) unre-
stricted manner.
Bi-speciﬁc T-cell engagers (BiTEs) provide an alternative
to CAR T-cells as they dispense with the need for ex vivo
manipulation and engineering of T cells.9 BiTEs consist of
small ﬂexible molecules composed of two antibody-derived
single chain variable fragments (scFv) linked in tandem.
One arm targets the TCR CD3 subunit, while the second
binds to a tumor-associated antigen (e.g., CD19). BiTEs
can redirect endogenous polyclonal T cells to sites of
tumors where, upon engagement with tumor antigen, they
promote the formation of immunological synapses. This is
followed by the release of perforins, granzyme B, and cyto-
kines, and selective killing of tumor cells independently of
MHC, costimulatory molecules, and antigen presenta-
tion.9,10 Blinatumomab, the ﬁrst in class BiTE, targets
CD19 and is highly effective in the treatment of chemo-
therapy-resistant relapsed/refractory B-ALL patients.11-13
As CD19 is exclusively expressed on B-lymphocytes, Blina-
tumomab cannot be used for the treatment of other cancers
with signiﬁcant unmet need, such as pancreatic cancer.
Therefore, BiTEs with broad applicability across a range of
cancer types are required.
Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is a
surface antigen present at high levels on an array of hematolog-
ical malignancies and solid tumors, including pancreatic,14,15
ovarian,14-18 breast,14,19-21 lung,14,22,23 and gastric cancer24 as
well as melanoma,25,26 Ewing sarcoma,27 chronic lymphocytic
leukemia,28-31 mantle cell lymphoma,32,33 and a subset of
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B-ALL.34,35 It is, therefore, a promising target for novel immu-
notherapy approaches, especially as it is expressed on cancer-
initiating cells, a subpopulation of cancer cells that are resistant
to standard cancer therapies but capable of self-renewal and
tumor recurrence.36,37 Furthermore, high ROR1 levels on
tumor cells correlate with metastases and poor outcomes.18-
21,38 ROR1 is absent on all critical organs but is expressed at
low level on adipocytes and parts of the gut, pancreas, and
parathyroid glands.14 Importantly, CAR T cells and a monoclo-
nal antibody directed against ROR1 have not demonstrated any
toxicity in animal models or humans.39,40 However, BiTEs tar-
geting ROR1 remain untested to date.
In this study, we describe the development and characteriza-
tion of a BiTE that targets ROR1. Our ROR1 BiTE mediated
antigen-speciﬁc cytotoxicity across a range of solid tumor cells
including pancreatic cancer cell lines with concurrent cytokine
production in vitro. In murine models, ROR1 BiTE prevented
the engraftment of pancreatic and ovarian cancer cells in xeno-
graft models and reduced the size of established subcutaneous
pancreatic tumors. Humanization of the binding arms, to mini-
mize immunogenicity, did not abrogate its effector function.
Therefore, our ROR1-BiTE provides a novel platform for T-
cell-mediated targeting of a range of solid tumors.
Materials and methods
Single chain variable fragment generation
Rats were immunized against the extracellular portion of ROR1
by Aldevron GmBH. Oligoclonal clones from the subsequent
hybridomas were single cell sorted and immunoglobulin heavy
and light chain sequences were isolated by 50 reverse ampliﬁca-
tion of cDNA ends (50 RACE) using the standard laboratory
protocols. Productive sequences, as identiﬁed by the Interna-
tional Immunogenetics Information System V-Quest tool,41
were cloned in frame with heavy and light chain constant
regions, and antibodies were generated by transient co-trans-
fection. Speciﬁc binding for ROR1 was demonstrated before
the conversion of the variable domains to scFvs in a heavy
chain-linker-light chain format.
Cell lines and reagents
PANC-1, SKOV-3, and HEK293T cells were obtained from
American Type Culture Collection (ATCC; LGC Standards).
MCF7 cells were obtained from Deutsche Sammlung von Mik-
roorganismen und Zellkulturen GmbH. SUIT-2, CFPAC1,
HPAF-II, MiaPaCa2, and PSN-1 cell lines were kindly provided
by Professor Aldo Scarpa (Department of Pathology and Diag-
nostics, University and Hospital Trust of Verona, Verona,
Italy). Other cell lines were from master cell banks within our
institute. HEK293T cells were maintained in Iscove’s Modiﬁed
Dulbecco’s Medium (ThermoScientiﬁc) supplemented with
10% fetal bovine serum (FBS) (ThermoScientiﬁc). All the other
cell lines were maintained in RPMI-1640 medium (Thermo-
Scientiﬁc) supplemented with 10% FBS, GlutaMAX, and
25 mM HEPES. Cells were cultured at 37C with 5% CO2. Cell
lines were screened for mycoplasma to ensure negativity before
functional assessment. ROR1 expression was assessed using a
commercial anti-ROR1 antibody (Clone 2A2, Biolegend) by
ﬂow cytometry.
BiTE generation
The ROR1 and control CD19 fmc63 scFvs were coupled to the
anti-human CD3 scFv (Clone OKT3) through a short amino
acid linker using gBlocks (Integrated DNA Technologies) and
overlapping extension PCR using Phusion DNA polymerase
(New England Biolabs). The BiTE open reading frame (ORF)
was cloned into the SFG retroviral vector upstream of a GFP
ORF, by NcoI/MluI restriction digestion. The two ORFs are
separated by an IRES region to obtain the SFG.ROR1-BiTE.
IRES.GFP or SFG.CD19-BiTE.IRES.GFP. To allow for the puri-
ﬁcation and detection of the BiTEs, we included an N-terminal
hexa-Histidine Tag.
Generation of HEK293T stable BiTE producer cells
Retroviral supernatant was produced in HEK293T cells using
the RD114 retrovirus envelope (RDF), PeqPam3 gag-pol, and
SFG.ROR1-BiTE.IRES.GFP or SFG.CD19-BiTE.IRES.GFP
transfer vectors following the standard laboratory protocols.
Supernatants containing retroviral vectors were harvested 48
and 72 h after transfection, immediately frozen on dry ice and
stored at ¡80C until further use. HEK-293T cells (1.8 £ 106)
were plated in 10 cm dishes in fresh media, and transduced
with 2 mL of supernatant containing retrovirus at 24 and 48 h
post-seeding. Transduced cells were incubated for 72 h in a
humidiﬁed incubator at 37C with 5% CO2 and sorted based
on GFP expression and tested for BiTE production.
BiTE production, puriﬁcation, and binding
HEK293T media containing BiTEs was collected and puriﬁed
by fast protein liquid chromatography (FPLC) using HiTrap
Talon binding columns with an AKTA Explorer (GE Health-
care Life Sciences). The quality of the BiTE puriﬁcation was
assessed by Coomassie staining after SDS-PAGE and quantiﬁed
using Pierce bovine serum albumin (BSA) standard dilutions
(ThermoScientiﬁc). ImageJ software was used for data analysis
(the U. S. National Institutes of Health). BiTEs were validated
by western blot using an horseradish peroxidase (HRP) conju-
gated anti-His antibody (Biolegend). The speciﬁc binding of
ROR1 BiTE or CD19 BiTE to target cells was assessed by
ﬂow cytometry using an anti-His Tag antibody (Abcam). Size
exclusion chromatography was undertaken with a Shimadzu
Nexera XR High-performance liquid chromatography
(HPLC) machine and Waters size exclusion chromatography
column (Bio-Analysis Center London).
T cell puriﬁcation
Peripheral blood mononuclear cells from healthy donors were
obtained after the centrifugation of fresh isolated volunteer
blood or buffy coats (NHS blood and transplant) on a density
gradient using Ficoll-Paque Plus (GE Healthcare Life Sciences).
In keeping with previous reports, freshly isolated T cells were
expanded for animal work only: T cells were plated at 1 £ 106
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cells per well in 24-well plates and expanded using CD3/CD28
beads (ThermoScientiﬁc) or 200 IU/mL of IL-2 (Miltenyi), and
kept in culture for between 24 h and 1 week before injecting
into mice. Freshly isolated unstimulated T cells were used for
all in vitro experiments.
Flow cytometry
Data were captured on an LSR Fortessa II ﬂow cytometer (Bec-
ton Dickinson) and analyzed using FlowJo software (Flowjo
LLC). Fluorescence activated cell sorting was undertaken on a
FACSAria Cell Sorter (Becton Dickinson).
Co-cultures assay
Co-culture assays were performed in 96-well plates, containing
1 £ 104 target cells, 1 £ 104 T cells, and puriﬁed BiTE at a con-
centration of 0.1 ng/mL–1 mg/mL. Twenty-four hours after the
addition of ROR1 BiTE or CD19 BiTE, supernatant was col-
lected for cytokine evaluation, which was performed by ELISA
following the manufacturer’s instructions (Biolegend). To
assess cytotoxicity, we used the CellTiter 96 AQueous One
Solution Cell Proliferation Assay (MTS) following the manu-
facturer’s protocol (Promega).
Immunohistochemistry
The heavy and light chains of our ROR1 scFv were cloned in
frame with the murine IgG1 constant and kappa constant
regions, respectively, and antibody was obtained from Absolute
Antibody Ltd. Normal pancreas and pancreatic tissue microar-
rays were obtained from US-Biomax. Slides were prepared
using the standard laboratory protocols. Brieﬂy, antigen
retrieval was undertaken by immersing slides in 0.01 M sodium
citrate buffer, pH 6.0 at 95C for 15 min before cooling and
rinsing once with PBS, and then blocked and stained with
ROR1 antibody (1:250) in PBS/Tween20, 0.05% BSA, 1% NaN3
4 mM for 60 min at room temperature. Slides were incubated
with the HRP-conjugated secondary, Histoﬁne Simple Stain
MAX PO (Nichirei), and developed using Stable DAB Plus
(Diagnostic Biosystems).
Humanization
The variable domain sequences of rat-derived ROR1 and
mouse-derived CD3 scFvs were searched against a human IgG
germline database. A human framework sequence with high
homology to rat or mouse antibody was chosen as human
acceptors for both light and heavy chains and humanized scFv
and antibodies were assessed for a speciﬁc binding against
ROR1 positive and negative cell lines.
Statistics
Statistical analysis was undertaken using appropriate statis-
tical tests in GraphPad Prism Version 6 for Windows. Sta-
tistical signiﬁcance was taken when p < 0.05 and error
bars represent standard deviation. At least two independent
experiments with different donor T cells were undertaken
for all in vitro experiments.
Animal studies
All animal works were performed under the authority of
the United Kingdom Home Ofﬁce Project and Personal
License regulations and were compliant with University
College London guidelines. Six- to eight-week-old female
Hsd:Athymic Nude-Foxn1nu mice (Charles Rivers Labora-
tories) received 2 £ 106 PANC-1.Luc or 5 £ 106 SKOV3.
Luc cells by intraperitoneal injection. PANC-1.Luc and
SKOV3.Luc luciferase expression was detected using D-
Luciferin (Melford Laboratories), which was injected intra-
peritoneally (IP) at a dose of 200 mg/mouse, and imaged
using the IVIS Imaging System 100 Series (Perkin Elmer)
at multiple time points. Living Image 4.4 software (Perkin
Elmer) was used to quantify bioluminescence imaging
(BLI) signal. For xenograft studies, 5 £ 106 of PANC-1
cells were mixed in an equal volume of Matrigel (Corning)
and were injected in the ﬂank of 6–8-week-old Hsd:Athy-
mic Nude-Foxn1nu. Once the xenograft were established
(minimum size 100 mm3), mice received 5 £ 106 T cells
by single tail vein injection, followed by a daily injection of
PBS, ROR1, or CD19 BiTE suspended in 0.1% BSA in PBS
(10 mg/kg/mouse). Tumor volume was calculated using the
ellipsoidal formula (length £ width2)/2.
Results
Design, expression, and puriﬁcation of ROR1 BiTE
We isolated a panel of anti-ROR1 antibodies that bound to
either the membrane distal immunoglobulin like (Ig) or
the more proximal frizzled (Fr) domain of ROR1 from a
rat hybridoma library (Fig. 1A). When converted into an
scFv format, they retained ROR1-speciﬁc binding and were
coupled to a murine CD3 scFv in a tandem structure sepa-
rated by a short ﬁve-amino acid (Gly4Ser) linker to create
an ROR1 BiTE molecule (Fig. 1B). BiTEs were stably
expressed in HEK-293T cells following gene transfer with
retroviral vectors. Supernatant harvested from these pro-
ducer cells was puriﬁed using metal-afﬁnity chromatogra-
phy with a distinct peak observed at approximately 40 mM
imidazole. SDS/PAGE electrophoresis showed a dominant
band at 52 kDa, corresponding to the expected molecular
weight of the BiTEs, with the veriﬁcation of the BiTE con-
ﬁrmed by Western blot analysis, respectively (Fig. 1C–E).
BiTEs can aggregate with storage affecting their binding
characteristics and effector function. To assess this, we
undertook independent size exclusion chromatography
HPLC, demonstrating <5% aggregation of the puriﬁed
BiTE at multiple dilutions (Fig. 1F, Fig. S1). Flow cytome-
try staining of the SUP-T1 cell line engineered to express
either human CD19 or ROR1 conﬁrmed speciﬁcity of the
CD19 and ROR1 BiTE, while human T cells showed spe-
ciﬁc binding to CD3 with both CD19 and ROR1 BiTEs
(Fig. 1G). Head-to-head comparison in a panel of ROR1
positive cancer cell lines demonstrated that the ROR1 BiTE
ONCOIMMUNOLOGY e1326437-3
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containing an scFv directed against the Fr domain yielded
consistently superior and reproducible cytotoxicity com-
pared with BiTEs targeting the Ig domain (Fig. 1H). There-
fore, this Frizzled domain scFv was selected for further
assessment.
ROR1 expression in pancreatic cancer and normal human
tissues from critical organs
We converted our ROR1 scFv into a full antibody to allow the
assessment of ROR1 expression in human tissue microarrays and
Figure 1. ROR1 BiTE design, characterization, and production. (A) Schematic representation of ROR1. The extracellular domain of human ROR1 is composed of three
domains: Immunoglobulin like, Frizzled, and Kringle domains. A panel of antibodies were isolated that targeted either the membrane distal immunoglobulin or more
membrane proximal frizzled domain. (B) Schematic of BiTE. Heavy chain variable regions (VH) and light chain variable regions (VL) are linked together to create single
chain variable fragments (scFv), the ﬁrst is speciﬁc for the ROR1, and the second for human CD3, separated by a short ﬂexible linker. A C-terminal hexa-Histidine Tag
allowed for detection and puriﬁcation. (C) Puriﬁcation of BiTEs was undertaken with a three-step imidazole elution protocol via FPLC. This yielded an initial large peak cor-
responding to non-speciﬁc binding to the HiTrap column followed by isolation of puriﬁed BiTE. (D) and (E) Coomassie staining of SDS PAGE showing the different protein
presents in each peak and representative western blot analysis of eluted fractions using anti-His Tag antibody (Lanes: 1 crude supernatant, 2 Flow-through, 3 and 4 Non-
speciﬁc binding peak, 5 protein ladder, 6 Pre-BiTE-peak fraction, 7 and 8 BiTE peak fractions). (F) Size exclusion chromatography HPLC of ROR1 BiTE at three different con-
centrations (1, 5 and 10 mg/mL) showing <5% aggregation (black arrow) compared with buffer alone. The double peak before main fraction (black star) represents the
buffer peak (see maginiﬁed version in Fig. S1). (G) Representative Binding Assessment of BiTEs. Binding was assessed against a panel of SUP-T1 modiﬁed cells lines or T
cells and detected with an anti-His antibody. The CD3, ROR1, and CD19 negative SUP-T1WT showed no binding with ROR1 or CD19 BiTEs. SUP-T1 cells engineered to
expressed either ROR1 (SUP-T1ROR1) or CD19 (SUP-T1CD19) showed binding with ROR1 and CD19 BiTE, respectively. To assess binding of the CD3 scFv, we used puriﬁed T
cells and incubated them in the presence of BiTEs. (H) Following puriﬁcation, quantiﬁcation, and normalization, cytotoxicity with immunoglobulin domain binding ROR1
BiTEs was compared against Fr-ROR1xCD3 at two different concentrations (100 ng/ml or 1000 ng/ml) in a killing assay where target cells and T cells were cultured in a
1:1 effector:target ratio. Cell viability was assessed at 24 h.
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resected tumors by immunohistochemistry using the identical
binding domain as used in the ROR1 BiTE. High ROR1 expression
was detected in pancreatic cancer specimens with positive staining
localized to the cytoplasm as well as the nucleus of cancer cells
(Fig. 2C and D). In contrast, only the islet cells stained for ROR1 in
samples of normal pancreatic tissues (Fig. 2A and B). ROR1
expression was also observed in regions of the stomach (Fig. 2J),
consistent with previous reports.14 Importantly, ROR1 was not
detected in normal tissue samples from the heart, liver, brain, kid-
ney, or lungs (Fig. 2E–I).
ROR-BiTE directs T cells to kill ROR1-expressing pancreatic
cancer cells in vitro
We next sought to assess the ability of our ROR1 BiTE to elicit
antigen-speciﬁc cytotoxic responses in vitro. In a standard cell
Figure 2. Immunohistochemistry staining of human tissues. Tissue microarrays were stained with anti-human ROR1 antibody with the same speciﬁcity and antigen bind-
ing arms as the BiTE. (A) and (B) Normal pancreas, with islet cells highlighted (arrow); (C) and (D) pancreatic cancer from two independent patients; (E) normal brain; (F)
normal kidney; (G) normal heart; (H) normal liver; (I) normal lung, and (J) normal stomach. All scale bars: 100 mm.
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viability assay, unstimulated T cells were co-cultured with the
ROR1 positive PANC1 pancreatic ductal adenocarcinoma cell
line at a 1:1 effector:target ratio (E:T) in the presence of either
ROR1 BiTE or control CD19 BiTE. The ROR1 BiTE demon-
strated signiﬁcant cytotoxicity with the killing of 97.3% of cells
(p < 0.001) (Fig. 3A) associated with T cell proliferation and
clustering (Fig. 3B) and a 15-fold and 11-fold increase in inter-
feron-g (IFNg) and interleukin-2 (IL-2) secretion, respectively
(Fig. 3C). Target cell lysis or cytokine release was not observed
upon the incubation of pancreatic cancer cells with ROR1 BiTE
in the absence of T cells (Fig. 3A, C, and D, designated “No T
cells”), demonstrating the need for dual speciﬁcity for killing of
tumor targets. Additionally, we did not observe any cytotoxicity
in co-cultures of PANC-1 cells with T cells without ROR1 BiTE
or in the presence of control CD19 BiTE. The latter is consis-
tent with the lack of CD19 expression on pancreatic cancer
cells. Dose-dependent killing was observed across a panel of
ROR1 positive pancreatic cell lines comprising SUIT-2,
CFPAC1, HPAF-II, MiaPaCa2, and PSN-1 with our ROR1
BiTE (mean cytotoxicity at 1 mg/mL, 96%). Signiﬁcant T-cell-
mediated killing was observed even at concentrations of 0.1 ng/
mL (Fig. 3D). However, T-cell-mediated killing did not corre-
late with ROR1 expression on target cells.
Antitumor response of ROR1 BiTE in two distinct murine
xenograft models
Currently, available animal models of pancreatic cancer are
limited in their reproduction of the complex tumor
environment. However, to provide in vivo proof of concept,
we assessed our ROR1 BiTE in two murine xenograft mod-
els. First, we injected 2 £ 106 PANC-1, ﬁreﬂy luciferase-
positive cells (PANC-1.Luc) into the peritoneal-cavity of
athymic nude mice followed by a single bolus administra-
tion of either 4 £ 106 (E:T ratio of 2:1) or 8 £ 106 (E:T
ratio of 4:1) human T cells. Mice received a daily intraperi-
toneal injection of ROR1 or control CD19 BiTEs (10 mg/
kg/mouse) for 5 d. Analysis on day 8 revealed PANC-1.Luc
engraftment, as assessed by non-invasive bioluminescence
imaging (BLI), was reduced in a T-cell-dose-dependent
manner by 11- or 15-fold in the 2:1 and 4:1 cohorts of
mice, respectively, compared with animals that received
CD19 BiTE (Fig. 4A, Fig. S2). We next undertook a subcu-
taneous model in which 5 £ 106 PANC-1 cells were
injected into the right ﬂank of athymic nude mice and were
allowed to establish to a minimum size of 100 mm3. Ani-
mals subsequently received a single tail vein administration
of 5 £ 106 puriﬁed T cells, followed by the intraperitoneal
administration of ROR1 BiTE at a dose of 10 mg/kg/mouse
daily for 7 d without exogenous cytokine support. Control
cohorts received either CD19 BiTE at an identical dosing
regimen or excipient (PBS). Treatment with ROR1 BiTE
reduced the growth of xenografts by greater than 50% dur-
ing the treatment period as assessed after 7 d of ROR1
BiTE therapy when compared with control animals (mean
size 62.2 mm3 vs. 119.7 mm3, p D 0.003). Longer follow-up
showed that despite only 7 d of ROR1-BiTE therapy and a
single infusion of T cells, the ROR1 BiTE-treated cohort
Figure 3. ROR1 BiTE mediates speciﬁc cytotoxicity against pancreatic ductal adenocarcinoma (PDAC) cell lines in vitro. (A) Cell viability assay demonstrates marked cyto-
toxicity against PANC-1 cell lines with ROR1 BiTE and unstimulated T cells but not with T cells alone or T cells with control CD19 BiTE (1:1 effector:target ratio; 1 mg/mL
BiTE). (B) T-cell clustering was seen when T cells were placed in the presence of target PANC-1 cells and ROR1 but not CD19 BiTE (CTRL). (C) IL-2 and IFNg secretion by T
cells in response to PANC-1 cells in the presence of ROR1 or CD19 BiTE. (D) Dose-dependent cytotoxicity with ROR1 BiTE in co-culture assays using a panel of PDAC cell
lines, which retains its cytotoxic activity at concentrations as low as 0.1 ng/mL. Flow cytometry analysis of ROR1 staining on cell lines compared with isotype control
shown for each cell line, values represent fold increase of MFI value compared with isotype control.
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maintained lower tumor volumes compared with the con-
trol mice (Day 28:mean size 171.2 mm3 vs. 361.2 mm3, p D
0.037), suggesting transient treatment with ROR1 BiTE can
lead to a durable antitumor responses (Fig. 4B).
ROR1 BiTE humanization
Our BiTE is composed of a rat anti-ROR1 and murine anti-
CD3 scFvs, leading to the potential for anti-BiTE-mediated
immune responses, potentially limiting its clinical efﬁcacy.
This is especially true as normal CD19 positive B cells are
ROR1 negative and would be spared, thus allowing production
of neutralising antibodies. In view of this, we undertook a
humanization program and grafted the rat and murine comple-
mentarity-determining regions of the parental scFvs onto
highly homologous acceptor human framework regions. The
antigen-binding characteristics, production, puriﬁcation, and
killing of ROR1 positive targets of the humanized BiTEs were
comparable to the original rat-mouse hybrid ROR1-CD3 BiTE
(Fig. 5A) with no evidence of loss of speciﬁcity when assessed
against ROR1 negative cell lines (data not shown). To conﬁrm
in vivo efﬁcacy of our humanized ROR1 BITE, mice received 2
£ 106 PANC1.Luc cells intraperitoneally and were then treated
with once weekly T cells (8 £ 106 human T cells; E:T ratio of
4:1) and fully humanized ROR1 BiTE. As with the non-human-
ized BiTE, we saw marked tumor reduction by day 8. Mice were
subsequently treated with weekly BiTE injections, with
extended follow up to 40 d conﬁrming long-term efﬁcacy
(Fig. 5B, Fig. S2).
In vitro and in vivo antitumor efﬁcacy of ROR1 BiTE across
a range of solid tumor lines
We next sought to test the ability of ROR1 BiTE to elicit anti-
gen-speciﬁc cytotoxic responses in vitro against other solid
tumor cells lines. T cells and ROR1 BiTE were co-cultured with
either ROR1 positive MDA-MB-231 or ROR1 negative MCF-7
breast cancer cell lines. Cytotoxicity and cytokine secretion
were only observed with the former, conﬁrming the presence of
ROR1 was essential for T cell activation (Fig. 6A and B).
Importantly, there was no evidence of T cell activation when
ROR1 BiTE was cultured with T cells in the absence of ROR1
positive target cells. We also assessed cytotoxicity against
SKOV-3, HOC-7, and HEY ovarian cancer cell lines that
express marginally different levels of ROR1 with killing and
Figure 4. In vivo assessment of ROR1 BiTE using luciferase positive PANC1 cell line.
(A) Intraperitoneal Engraftment: 2 £ 106 PANC-1.Luc cells/mouse were adminis-
tered followed by a single dose of puriﬁed human T cells injection intraperitoneally
(8 £ 106 CTRL BiTE group; 8 £ 106 and 4 £ 106 ROR1xCD3 BiTE groups 1 and 2,
respectively). BiTEs were injected daily at 10 mg/kg/mouse for 5 d. PANC-1.Luc
engraftment was assessed by in vivo bioluminescent imaging (BLI). (B) Established
xenograft model: PANC-1 cell lines (5 £ 106) were injected in the right ﬂank of
immunocompromised athymic nude mice and xenografts were established to a
minimum size of 100 mm3. Mice then received a single intravenous injection of
puriﬁed T cells (5 £ 106) and were treated with ROR1 BiTE, CD19 BiTE or PBS at
10 mg/kg/d iv daily for 7 d and the size of the tumor measured by caliper. Follow-
up of these animals at day 28 showed that ROR1 BiTE treated mice had lower
tumor volumes compared with the control cohorts despite no additional ROR1
BiTE administration.
Figure 5. Fully humanized ROR1 BiTE in vitro and in vivo efﬁcacy. (A) Rat/Mouse non-humanized ROR1 BiTE and fully humanized ROR1 BiTE showed equivalent afﬁnity for
ROR1 and CD3 against PANC1 positive target cells. Humanized ROR1 BiTE led to equivalent cytotoxicity against PANC1 target cells and T cells compared with parental
non-humanized BiTE. (B) Mice received 2 £ 106 PANC-1.Luc cells/mouse intraperitoneally followed by three doses of puriﬁed 4 £ 106 human T cells. Humanized BiTE was
injected once per week at 10 mg/kg/mouse and PANC-1.Luc engraftment was assessed by in vivo bioluminescent imaging (BLI).
ONCOIMMUNOLOGY e1326437-7
D
ow
nl
oa
de
d 
by
 [U
CL
 L
ibr
ary
 Se
rv
ice
s] 
at 
02
:06
 29
 A
ug
us
t 2
01
7 
cytokine release observed against all cell lines (Fig. 6C and D)
but as before, did not observe a correlation between ROR1
expression and cytotoxicity. In vivo efﬁcacy was assessed in
athymic nude mice injected intraperitoneally with SKOV-3
cells expressing ﬁreﬂy luciferase (SKOV-3.Luc) together with a
single administration of T cells in an E:T ratio of 2:1 ratio. Mice
were treated for 5 d with ROR1 BiTE, or control CD19 BiTE.
The ROR1 BiTE prevented engraftment of SKOV-3.Luc cells
compared with the CD19 BiTE treated animals that had sig-
niﬁcant tumor burden at day 12 (Fig. 6E, Fig. S2). Finally,
we tested our ROR1 BiTE in vitro against a panel of ROR1
positive cell lines representing melanoma (T618A), glioblas-
toma (U-251, A 172), prostate (DU145, PC-3), and hepatic
cancer (SK-Hep-1, HUH7) and conﬁrmed signiﬁcant cyto-
toxicity against all of these ROR1 positive cell lines, demon-
strating wider applicability in targeting a range of tumor
subtypes (Fig. S3).
Discussion
From a panel of rat anti-human ROR1 antibodies, we selected
an scFv that targeted the cysteine-rich frizzled domain of
ROR1 as it consistently yielded superior and reproducible cyto-
toxicity compared with scFv that targeted the ROR1-immuno-
globulin-like domain. In keeping with this, a bispeciﬁc
antibody targeting the membrane proximal domain of FcHR5
showed superior cytotoxicity compared with one targeting a
membrane distal domain, and this was shown to be due to
more efﬁcient cytotoxic synapse formation with the former.42
Our resulting ROR1 BiTE facilitated efﬁcient T-cell-mediated
killing of pancreatic and ovarian cancer in vitro and in vivo as
well as a range of solid tumor cell lines of different histological
origins. Variation in ROR1 expression between tumor types, as
well as within cells lines derived from tumors of the same histo-
logical origin, was observed. However, our ROR1 BiTE was able
Figure 6. ROR1 BiTE provides in vitro and in vivo speciﬁc cytotoxicity against breast and ovarian cancer cell lines. (A) Flow cytometry staining of ROR1 on MDA-MB-231
cells lines and MCF7 breast cancer cell lines compared with isotype control, values represent fold increase in MFI value. (B) Cytotoxicity and cytokine secretion against
ROR1 positive MDA-MB-231 but not ROR1 negative MCF7 cell lines as assessed by a cell viability assay using 1 mg/mL ROR1 BiTE at 24 h compared with CD19 BiTE (1:1
Effector: Target ratio). (C) Flow cytometry staining of ROR1 on SKOV3, HOC-7, and HEY ovarian cancer cells lines compared with isotype control, values represent fold
increase in MFI value. (D) Cytotoxicity and IFNg secretion of ovarian cancer cell lines as assessed by a cell viability MTS assay using 1 mg/mL ROR1 BiTE at 24 h compared
with CD19 BiTE. (E) 5 £ 106 SKOV-3.Luc cells/mouse were administered followed by a single dose of puriﬁed 10 £ 106 human T cells injection intraperitoneally. BiTEs
were injected daily at 10 mg/kg/mouse for 5 d. SKOV3.Luc engraftment was assessed by BLI.
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to mediate efﬁcient and equivalent killing of tumor cells with
low and high levels of ROR1 with relatively low effector to tar-
get ratio. Optimal T cell activation required dual speciﬁcity as
our ROR1 BiTE could not elicit functional T cell activation or
cytokine release in the absence of engagement with ROR1, as
illustrated with the ROR1 negative MCF7 cell line. Interest-
ingly, a relatively low concentration of ROR1 BiTE was
required (nanogram quantities) when compared with doses
(microgram quantities) of conventional antibodies used in
clinic, to mediate killing of tumor targets. This indicates that
the avidity gained by bispeciﬁc binding, in combination with
the large signal ampliﬁcation by the T cell receptor, enhanced
the potency of this bi-speciﬁc molecule.43 Moreover, to mini-
mize against potential immunogenicity, we undertook a
humanization program of both the ROR1 and CD3 scFvs and
developed a fully humanized BiTE that facilitates equivalent
cytotoxicity against target cell lines in vitro and retains its effec-
tor function in vivo.
Our study conﬁrms previous ﬁndings that ROR1 is
expressed on some normal tissues,14 which raises the possibility
of on-target off-tumor toxicities. However, Cirmtuzumab, a
humanized high afﬁnity anti-ROR1 monoclonal antibody
directed toward the immunoglobulin-like domain of ROR1,
has been safely administered to 12 patients with CLL with no
signiﬁcant toxicity reported (NCT02222688).39,40 Plans are in
place to evaluate the same antibody in patients with breast can-
cer (NCT02776917). In addition, the administration of rela-
tively high dose of functional ROR1-CAR T cells (5 £ 108 T
cells/kg) in non-human primates did not result in any toxicity,
despite similar levels and patterns of ROR1 expression in non-
human primates compared with humans.39 Two ROR1 CAR
T-cell Phase I/II studies have been registered for patients with
hematological and solid malignancies (NCT02194374,
NCT02706392).
These data are reassuring but our plan is to undertake a cau-
tious evaluation of our own humanized ROR1-BiTE entailing a
detailed independent immunohistochemistry study to exclude
the potential of unidentiﬁed cross reactivity of our scFvs with
normal human tissues. This would be followed by the system-
atic evaluation of high ROR1 BITE doses in non-human pri-
mate toxicology study before progressing to humans.
Given their promise, BiTEs against a range of tumor associ-
ated antigens have been generated9 including CD20,44 B-Cell
maturation antigen (BCMA),45 epithelial cell adhesion mole-
cule,46 and carcinoembryonic antigen (CEA),47 but the majority
of clinical evaluation has so far been focused on patients with B
cell malignancies with Blinatumomab. A number of trials with
BiTEs against other targets are ongoing including BCMA
(NCT02514239), CEA (NCT02291614), and PSMA
(NCT01723475). Blinatumomab has resulted in high response
rates in groups of patients who otherwise carry a poor progno-
sis including those with relapsed/refractory B-ALL or high-
grade B cell non-Hodgkin’s lymphoma.11,12 CD19 targeting
CAR T-cells have demonstrated similar high levels of efﬁcacy,
thus providing clinicians with a choice of immunotherapies for
patients with B-cell malignancies. Direct comparison of the efﬁ-
cacy of CD19 BiTE when compared with CD19 CAR T-cells is
not possible in the absence of randomized control trials as they
are in different stages of development. In addition, published
reports often have small patient numbers with variable levels of
pre-treatment disease burden. Cytokine release syndrome
(CRS) and neurologic toxicity, the two main worrying compli-
cations, have been observed with both Blinatumomab and
CD19 CAR T-cells therapies. The incidence of CRS with BiTEs
may be lower, based on the published reports.48 Additionally,
the ability to increase the dose of BiTEs in a stepwise manner
and switch off the infusion, should toxicity occur, provides
BiTEs with a theoretical advantage over CAR T-cells, which
can expand in vivo in an unpredictable manner.
A major disadvantage of CAR T-cell therapy when com-
pared with an off-the-shelf treatment like BiTEs is that it
requires a complex, multi-step, labor intensive ex-vivo T-cell
manufacturing process that is patient speciﬁc. The ﬁnal compo-
sition CAR T-cells are often heterogeneous and vary in the
number of gene modiﬁed T cells obtained, as well as speciﬁc
cell composition and ﬁtness.49 Furthermore, access to CAR T-
cells is limited to a relatively small number of academic centers,
with overall manufacturing capacity at present being insufﬁ-
cient to meet demand. A key advantage of CAR T-cells is their
persistence in vivo, potentially resulting in durable antitumor
response, while the risk of relapse remains high upon discon-
tinuation of BiTE therapy, especially in aggressive malignan-
cies. However, the potential of targeting ROR1 expressed by
cancer-initiating cells such as those derived from ovarian can-
cer and glioblastoma36,37 may mitigate the risk of relapse and
raise the potential of a cure.
In summary, we provide the ﬁrst systemic evaluation and
proof of concept of an ROR1 BiTE and show T-cell-mediated
efﬁcacy against a panel of solid tumors, raising the prospects of
targeting a range of tumor types. Immunotherapy for solid
tumors faces several challenges; combinational therapy may be
required to facilitate efﬁcient T cell inﬁltration, effector func-
tion and reversal of the immunosuppressive microenviron-
ment. However, our humanized ROR1 BiTE represents a
rational therapy for cancer patients with high-unmet need such
as those with aggressive tumors like pancreatic cancer and war-
rants further assessment in clinical trials.
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